Development of a Multi-Purpose Comprehensive Physiologically Based Pharmacokinetic Model for Crizotinib: An Example Application in Bioequivalence Assessment between Oral Solution and Granules in Pediatric Subjects
Authors:
Open Access
- 28 July 2025
- journal article
- Published by Springer Nature in The AAPS Journal
- Vol. 27 (5) , 126
Abstract
Crizotinib exhibits a complex drug-drug interaction as it is a CYP3A4 substrate and acts as both a time-dependent inhibitor and inducer of the enzyme. Absorption of crizotinib is also complex as it exhibits a prolonged absorption phase. The primary objective of this research was to develop a comprehensive physiologically based pharmacokinetic (PBPK) model to mechanistically describe both metabolism and absorption of crizotinib. The established crizotinib adult PBPK model was extrapolated to pediatric population using the modified CYP3A4 ontogeny profile to evaluate the pharmacokinetic (PK) profile after a single dose administration of crizotinib under the fasted condition in pediatric population age between 1 to 6 years old. The model was further applied to conduct virtual bioequivalence (BE) trials including clinically observed intra-subject coefficient of variation (ICV%) in both adult and pediatric populations. In adult subjects, the estimated geometric mean ratio for AUCinf and Cmax for oral solution (OS) vs granules formulation was 98.33 and 89.94, respectively with probability of demonstrating BE in adults of 100% for AUCinf and 90.3% for Cmax. In pediatric subjects, the probability of demonstrating BE success was 99.7% for both AUCinf and Cmax. The high probability of BE was replicated with the assumed higher ICV of 29% in pediatrics for both AUCinf and Cmax. The granules (commercial formulation) can be considered BE to OS (Phase 3 clinical formulation) in adults, as well as pediatric subjects aged between 1 to 6 years old. Graphical AbstractKeywords
This publication has 26 references indexed in Scilit:
- Integrating Clinical Variability into PBPK Models for Virtual Bioequivalence of Single and Multiple Doses of Tofacitinib Modified‐Release Dosage FormClinical Pharmacology & Therapeutics, 2024
- Regulatory utility of physiologically based pharmacokinetic modeling for assessing food impact in bioequivalence studies: A workshop summary reportCPT: Pharmacometrics & Systems Pharmacology, 2023
- Utilization of Physiologically Based Pharmacokinetic Modeling in Clinical Pharmacology and Therapeutics: an OverviewCurrent Pharmacology Reports, 2020
- Establishing virtual bioequivalence and clinically relevant specifications using in vitro biorelevant dissolution testing and physiologically-based population pharmacokinetic modeling. case example: NaproxenEuropean Journal of Pharmaceutical Sciences, 2020
- Predictive Performance of Physiologically Based Pharmacokinetic (PBPK) Modeling of Drugs Extensively Metabolized by Major Cytochrome P450s in ChildrenClinical Pharmacology & Therapeutics, 2017
- Literature Review of Gastrointestinal Physiology in the Elderly, in Pediatric Patients, and in Patients with Gastrointestinal DiseasesJournal of Pharmaceutical Sciences, 2016
- Evaluation of crizotinib absolute bioavailability, the bioequivalence of three oral formulations, and the effect of food on crizotinib pharmacokinetics in healthy subjectsThe Journal of Clinical Pharmacology, 2014
- A Re-evaluation and Validation of Ontogeny Functions for Cytochrome P450 1A2 and 3A4 Based on In Vivo DataClinical Pharmacokinetics, 2014
- Paediatric Development: Gastrointestinal2014
- Do pellet formulations empty from the stomach with food?International Journal of Pharmaceutics, 1993